Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00393263 | Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus | PHASE2 | COMPLETED | 38 | — | — | Oct 1, 2006 | Oct 1, 2009 | May 12, 2014 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | pimecrolimus |
| 2 | ACTIVE_COMPARATOR | clobetasol |
| Name | Type | Description |
|---|---|---|
| pimecrolimus and clobetasol | DRUG | - |
| clobetasol 0.05% cream | DRUG | twice daily for three months |
Inclusion Criteria: * Female, 18 years or older. * With a diagnosis of biopsy proven active vulvar lichen sclerosus. * Signed written informed consent. * Willingness and ability to comply with the study requirements. * Negative urine pregnancy tests must be documented for all females of childbearin...